Broker Reiterates RMB 40B Valuation for Dizal Pharma on Global Launch of Sunvozertinib

Very Bullish

What Happened

The broker reiterates a RMB 40 billion target valuation for Dizal Pharma, citing the global commercialization harvest period for sunvozertinib starting in 2H26, and the receipt of a $600 million upfront payment from AstraZeneca.

Bottom Line

Broker remains bullish on Dizal Pharma, expecting significant value realization from sunvozertinib's global launch and other pipeline assets.

Free preview — more China A-share & HK research · About Us · Legal & Privacy